Jan 29, 2025, 22:05
Preliminary Safety, Antitumor Activity, and ctDNA Changes with Zoldonrasib in KRAS G12D PDAC
Bertrand Delsuc, CEO and Founder at Biotellytics, shared on X:
“Preliminary Safety, Antitumor Activity, and ctDNA Changes with Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with KRAS G12D PDAC from a Phase 1 in Advanced Solid Tumors.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 29, 2025, 22:05
Jan 29, 2025, 22:05
Jan 29, 2025, 22:05
Jan 29, 2025, 22:05
Jan 29, 2025, 22:05
Jan 29, 2025, 22:05